

Index

Abdellaoui, M., 93 abdominal pain, and computer-aided diagnosis, 389 abortion, and prenatal testing, 260 absorbing state, and Markov processes, 44 accuracy analysis: baseline assumptions, 213-14; combining of predictions, 241; decomposition studies, 231-5; definitions of terms, 243-7; formulas and symbols, 247-9; lens model analysis, 235-7, 242; measures of, 214-26, 242; methodological issues, 226-8; overview of, 211-14; potential modifiers of, 237-41; studies of physicians, 228-31 Acton, J. J. P., 323 adaptation, and health states, 302 adjusted normalized discrimination index (ANDI), 225 administrative and billing systems, and cost-effectiveness analysis, 172 advanced directives: bioethics, 256; patient education, 338 adverse reactions, and clinical drug trials, African Americans, and utility ratings for health states, 322 age, and decisions to withdraw life support, 262-3 Agency for Health Care Policy and Research, 389 aggregated approach, to lens model analyses, 236 AIDS (acquired immunodeficiency syndrome): patient empowerment, 336; progression of and level of CD4 cells,

infection to, 41, 50 AI/Rheum system, 373 alcohol-induced hypoglycemia, 278 Alzheimer's disease, 315-16 AMA Family Medical Guide, 344 anesthesiology, 187, 202 angina, and patient preferences, 298, 300, antibiotherapy management program, 374-5 antibiotics: cost-effectiveness analysis, 171-2; decision tree and prescription of, 25; intervention to reduce overprescription of, 396-401 anticoagulant therapy, and atrial fibrillation, 13-14, 151-6 APACHE II model, 241 APOE testing, 315-16 Arden syntax, 375 Arkes, H. R., 185-6, 188, 194-5, 205 ARPANET (computer network), 345 artificial intelligence, 15 artificial judges, 213 Asch, David A., 177, 262 Ascher, W., 153-4 Asian flu, 189 association-based decision errors, 205 asymmetric funnel plots, 127-8 atrial fibrillation (AF), and anticoagulant therapy, 13-14, 151-6 attention-focusing tools, and computer-assisted clinical decision support, 368-9 attraction effect, and choice options, 194

52-4; rate of progression from HIV



424 Index

autonomy, and bioethics, 254, 255, 258-64, averaging out, and decision tree, 26-7, 31, 33 back pain, 68 Baron, J., 196, 198 Bayesian models: computer-assisted clinical decision support, 371, 372; meta-analyses of randomized trials, 124, 126 Bayes' Theorem: decision tree for HIV screening, 30-1, 32f; hypothesis testing, 187, 188; influence diagram, 36 Bayoumi, A. M., 93-4 Beauchamp, T., 254 Beck, R. J., 49 bedside clinical decisions: assessment of patient utility, 6; decision analysis, 316-19; decision boards as visual aids, 306; risk attitudes, 298; utility assessment, 319-23 Ben-Bassat, M., 372 beneficence, and bioethics, 254 benign prostatic hypertrophy (BPH), 6, 298, 318-19 Bernstein, L. M., 191 Berwick, D. M., 239 between-study variance, and randomized trials, 124 Bezembinder, T. G. G., 67 biases: accuracy analysis, 218, 233; bioethics, 258, 262; correction of, 204-6; diagnostic review bias, 234; ecological bias, 126; English-language bias, 120; experimental conditions, 112; group decision making, 268; hindsight bias, 185-6, 187, 205; incorporation bias, 234; judging probability of events, 184-8; omission bias, 195-7, 198, 258; outcome bias, 186-7; preferences and values, 188-200; presentation bias, 121; prevalence of, 204; psychological explanations for, 17; publication bias, 127; retrieval bias, 132; selection bias, 227; sunk cost bias, 194-5; test review bias, 234; and time, 200-4; verification bias, 233 bibliographic databases, 121 Billi, J. E., 188 binary lotteries, 88-9

bioethics: mutual feedback, 264-5; patient autonomy and informed consent, 258-64, 314; principles and limitations of, 254-8; on theoretical and empirical levels, 253 BIOSIS database, 121 Bleichrodt, H., 73-4, 93 Blumer, C., 195 Bornstein, B. H., 195 Boyd, N. F., 67 branches, of decision tree, 24-5 breast cancer, 318, 335, 343, 393 Breast Cancer Lighthouse (Gold Standard Media), 343 Brier score, 215, 216 Brigham and Women's Hospital, 369 brochures, and health information, 339 Brock, D., 314 Brown, K., 188, 394 bulletin board services (BBSs), 346 calibration curves, and accuracy analysis, 215, 219-26, 243 cancer. See breast cancer: cervical cancer; lung cancer; ovarian cancer; prostate CANCERLIT database, 121, 346 CANCERNET (National Cancer Institute), capital, social opportunity cost of, 176 capitation, and cost-effectiveness analysis, 10 Caplan, R. A., 187 cardinal utility, 76 cardiopulmonary resuscitation (CPR), 263, 264, 402 caregivers: health information, 355; opportunity costs and unpaid, 174 Caro, J. J., 151 case-based reasoning, 406 case management meetings, 412-13 CASNET/Glaucoma system, 372-3 CD4 lymphocytes, and HIV screening, 52 - 4CD-ROMs: health information for patients, 342, 365-6; training of physicians, 412 Cebul, R. D., 396 Census Bureau, 154 cephalosporin, 171-2 cerebrovascular disease, 54



Index 425

certainty effect, and decision biases, 199-200, 205 certainty equivalents, and utility assessment, 84-5, 86, 96-7, 99, 101-2 cervical cancer, 164 Chalmers, T. C., 122 Chancellor, J. V. M., 304 chance nodes, and decision tree, 24f, 25, 27, 34, 45 Chapman, G. B., 191, 194, 195, 351 Chen, S., 198 Cher, D. J., 298, 325 Chewning, B., 350 childbirth, and anesthesia, 202 Childress, J., 254 Chorionic villus sampling, 317 Christensen, C., 191, 279 Christensen-Szalanski, J. J. J., 202 CINAHI database, 121 clinical algorithms, 370 clinical health policy, 146-7 clinical pathways: computerized versions of, 368; cost-effectiveness analysis, 166 clinical practice: confirmation biases, 188; ethical principles, 255; framing effects, 190; policy modeling, 152-3, 155. See also bedside clinical decisions; computer-based clinical decision support; guidelines Clinical Reference Systems, 343 clinical strategies, and decision models, 8 clinical trials: adverse reactions and safety issues in, 118; computer-assisted clinical decision support, 377-8; cost-effectiveness of, 113; eligibility criteria for, 114-15. See also randomized, controlled trials Coast, J., 304 Cochrane Collaboration, 119, 121 cognitive feedback, and multiple cue probability learning, 392 cognitive task analysis, 410 Cohen, Joshua, 177 coherence, and assessment of judgments, cohort simulation, and Markov processes, 47-51 Col, N. F., 21 colonoscopy, 203 commission, and omission-commission

communication: group decision making, 273; patient health information, 338-9; physician-patient relationship, 335, 353 community, cost effectiveness analysis and preferences of, 10 comorbidities, and patients' health states, comparators, and cost-effectiveness analysis, 164-6 Complete Guide to Symptoms and Illness (Great Bear Technology, Morgan, CA), 343 completion lag, and meta-regression analyses, 127 complexity: decision models, 22; Markov processes, 51-4 compliance, and patient involvement in decision making, 336 Comprehensive Health Enhancement and Support System (CHESS), 335-6 computer-based clinical decision support systems (CDSS): attention-focusing tools, 368-9; definition of, 362; diagnosis of abdominal pain, 389; ethical and legal issues, 376-9; future of, 380; information resources for, 364-8; patient-specific consultations, 369-75; potential value of, 363. See also computers computer-based patient records (CPRs): computer-based clinical decision support systems, 364-5; practice guidelines, 16 computers: correction of biases, 205; decision modeling, 15, 349; health information for patients, 341-5, 346-8, 349-56; information management tools and physician decision making, 394-6; patient records, 16; role of in supporting or altering physician decision making, 6; team decision making, 280; utility assessment, 323-6. See also computer-based clinical decision support systems; software programs; World Wide Web confidence, and accuracy of judgments, confidence intervals, and randomized trials, 117 confirmation bias, 187-8

conflict resolution, and physicians' scripts,

distinction, 196-7



426 Index

confounding variables, and subgroup analyses, 115 congestive heart failure, 231 Connors, A. F., 188, 240 consumerism, and patient involvement in health care, 334, 356 Consumer Price Index, 173 content validity, and utility assessment, context: analysis of physicians' scripts, 410, 411; of clinical health policy, 147; of decision models, 22 contingent valuation, and health states, 323 control groups, in randomized trials: event rate, 128-9; use of experimental treatment by, 113 convergent validity, and utility assessment, 296 Cooksey, R. W., 236 coping, and psychology of health states, coronary artery disease, 231 coronary care unit (CCU), 160 Coronary Heart Disease Policy Model, 54, 149-50 cost-accounting systems, 17 cost-benefit analysis: compared to cost-effectiveness analysis, 158; contingent valuation for heath states, cost-effectiveness analysis (CEA): anticoagulant therapy management, 14; bioethics, 257, 261-2; of clinical trials, 113; contributions to medical decision making, 159-62; decision models, 39; definition of, 3-4, 158; discounting, 175-6; framing of analysis, 163-6; future of health care system, 17; guidelines, 390-1; health policy, 5; management and valuing of resource use, 170-4; perspectives and, 9-11, 163-4, 166, 170-4, 177; reporting and use of, 176-7; risk attitudes, 299 cost-generating events, and cost-effectiveness analysis, 171 covariance decomposition, and accuracy analysis, 218-26 Covell, D. G., 367 Cowlin, R. A., 280 Cox proportional hazards regression, 115

Cretin, S., 175, 202 criterion validity, and utility assessment, cue form and cue strength, and accuracy analysis, 243-4 culture: access to health information, 352-3; diversity in decision making teams, 275-6 cumulative probabilities, and rank-dependent utility theory, 88 cumulative prospect theory (CPT), 105-6 cumulative utility, and Markov processes, cycles, and Markov processes, 43 cycle tree, and Markov processes, 45, 46f Dales, R. E., 191 databases: computer-assisted clinical decision support, 365, 370-1; development of large-scale on clinical outcomes, 15-16, meta-analyses of randomized trials, 120, 121; patient education, 343, 346 Dawson, N. V., 186, 188, 238, 239 decision analysis (DA): bedside clinical decisions, 316-19; computerized support for utility assessment, 323-6; definition of, 3, 20; diagnostic rules, 388-9; evidence-based guidelines, 389-91; granularity, 22; identifying decision maker, 314-15; improvement of medical decision making, 387-8; individualizing model of, 315-16; modeling of event pathways, 168; quantitative techniques, 4; type of problems relevant to, 21; utility assessment, 319-23; value-focused approach, 326 decision boards, as visual aids, 306 decision models: advantages and disadvantages of methods, 60-2; background to, 20-4; and computers, 349; cost-effectiveness analysis, 39; decision trees, 24-33; definition of, 20; discrete event simulation, 59-60; future of health care system, 14-16; influence diagrams, 33-6; Markov processes, 39-54; normative, descriptive, and prescriptive, 3-6; overview of, 11-12; sensitivity analysis, 36-9 decision rules, and end-of-life care, 411



Index 427

decision theory: as consequentialist theory, 195-6; health care system, 7-9; improvement of medical decision making, 387-96; normative model of, 3-5; physicians' scripts, 405-13; training of physicians, 391-3; as two-way street, 7 decision trees: advantages of, 60; Down syndrome as example of, 259–60; HIV screening as example of, 24-33, 39-41 decision weights, 198-200 decomposition studies, and accuracy analysis, 231-5 De Dombal, F. T., 371 Delbanco, T. L., 352 Deneffe, D., 97-8 DerSimonian, R., 124, 135 descriptive invariance, and framing effects, 190 descriptive models: for health policy, 149; macro-level analyses, 292, 293; for medical decision making, 5 diagnosis: confirmation bias, 187-8; decisions involving uncertainty, 184; hindsight bias, 185, 187; team decision making, 277-8. See also diagnostic rules; diagnostic tests diagnosis-related groups (DRGs), diagnostic review bias, 234 diagnostic rules, and decision analysis, 388-9 diagnostic tests, and meta-analyses of randomized trials, 129-31 Directory of Consumer Health Informatics (Kieschnick et al., 1996), 342 discounting and discount rates: biases in decision making, 201-2, 203; cost-effectiveness analysis, 175-6 discrete event simulation, 59-60, 61t, 62 discrimination index (DI), and accuracy analysis, 215, 217, 218, 225, 243 disease: decision models and process of, 23; preferences and experience of, 302, distal events, and decision tree, 25 Doherty, M. E., 187-8 Dolan, P., 321 "do no harm" principle, 254 do-not-resuscitate (DNR) orders, 263, 264,

double-masked, randomized trials, 111, downstream events, and decision tree, 25, Down syndrome, 259-60, 316-17 drug-drug interactions, 344 Drummond, M. F., 73, 77 duration neglect, 203 DXplain diagnostic decision support system, 366 dynamic influence diagrams, 58-9, 61t, 62 echocardiography, 13, 14 ecological bias, 126 Eddy, D. M., 8, 168, 174 education: access to health information, 354-5; computer software, 342-5; evidence-based medicine, 14; informed consent and advance directives, 338; noncompliance, 336; physician-patient relationship, 335. See also health information; training effect size, and meta-analysis of randomized trials, 123 egalitarianism, and bioethics, 254, 257, 261 Einhorn, H. J., 240 Eisenberg, J. M., 171–2 eligibility criteria, for clinical trials, 114-15 eligibility-enrollment log, for clinical trials, 115 Elstein, A. S., 191 e-mail, and health information, 342, 345-6, 351-2 Emanuel, E. & L., 314 EMBASE database, 120, 121 embedded decision form, 25-6 embedded models: for decision analysis, 5; for health policy, 150, 151, 153, 154 emergency departments, and evaluation of chest pain, 228 emergency medical information, 344 Emler, A. C., 195 empowerment, and patient involvement in medical care, 335 encyclopedias, and patient information, 343 Endicott, J., 274 end-of-life care: bioethics, 255-6, 262-4; intervention to reduce futile, 401-5, 406; physicians' scripts, 408, 409-10

401, 403



More information

428 Index

endpoints, multiple and secondary in randomized trials, 117 end-stage liver disease, and discrete event simulation, 59 English language bias, 120 enlightenment model, of health policy, Equivalence Technique, and health state valuation, 294 equivalent risk groups, and accuracy analysis, 244 Eraker, S. A., 74, 81, 86-7, 99-100, 298 errors, identification of in physician's decision process, 6. See also biases ethics, and computer-based clinical decision support, 376-9. See also bioethics EuroQol system, 292, 293, 304 euthanasia: bioethics, 255; omission-commission distinction, 197 evaluation method, and decision modeling, 60 even-chance gambles, 84 event detection and notification system, event pathways: cost-effectiveness analysis, 166, 167; decision analysis and modeling of, 168 event rate, control groups and meta-analyses of randomized trials, evidence-based medicine: clinical health policy, 156; definition of, 4, 110; external validity, 114; future of health care system, 14-18; guidelines, 389-91; individual and population applications of, 133; sensitivity analysis and exploration of heterogeneity, 133-4; statistically nonsignificant study results, 132-3. See also meta-analysis; randomized, controlled trials excess forecast variance, 218 expected utility (EU) theory: decision weights, 198-9, 200; definition of, 3; normative validity of, 66; rank-dependent utility theory, 88-92; theory of preferences, 65; utility assessment, 66, 75-88, 104-5 expected value, and decision tree, 27 experience, of physician and accuracy

expertise: patient education, 354-5; of physician and accuracy analysis, 238-9 EXPERT system, 373 explicit guideline development, 8 facilitative models: for decision analysis, 5; for health policy, 150, 153, 154 fairness, and bioethics, 254-5 false positives, and HIV screening, 27-8 feedback: accuracy of judgments, 239-40; bioethics, 264-5; multiple cue probability learning and cognitive, 392 fee-for-service arrangement, 10 first aid, and emergency medical information, 344 First Aid Tutorial (Marketing Services Corporation of America, Brookfield, WI), 344 fixed-effects models, 116, 124 flow charts, as decision making tools, 370 folding back, and decision tree, 26-7, 31,33 follow-up, and meta-analyses of randomized trials, 128 Food and Drug Administration (FDA), 377 forecast-outcome covariance, 218-19, 226 Forsythe, D. E., 369 Foundation for Informed Decision Making, 351 Foundation for Shared Decision Making, framing effects, and decision biases, 189-91, 192-4, 205 Frederickson, B. L., 204 free-standing models: for decision analysis, 5; for health policy, 149-50, 151, 154 Froberg, D. G., 77, 302 Fryback, D. G., 73, 169-70, 304, 308 gain/loss framing, 190 GALEN database, 375 gambling effect, and preferences, 297

Garber, A. M., 325

Gardner, R. M., 377

Gaucher disease, 325

time costs, 174

gastroesophageal reflux, 195

gender: team decision making, 274-5;

experimental control, and design of

clinical studies, 111-13

analysis, 238-9



Index 429

general-variance fixed model, and treatment effects in randomized trials, 134 - 5Gigerenzer, G., 394 Gilovich, T., 198 Giuse, N. B., 375 glaucoma, and computer-assisted decision making, 372-3 gold standard test: accuracy analysis, 233; group decision making, 268, 277; utility assessment, 295 Goldstein, M. K., 325 Gonzalez, Richard, 93, 103, 105 Goodman, K. W., 376 granularity, and decision analysis, 22 Greek oracle model, for computer-assisted decision making, 374 gross costing, and cost-effectiveness analysis, 172 group decision making. See team decision making groups of states, and Markov processes, groupthink, 275 Gruppen, L. D., 188 guidelines: for anticoagulant therapy in atrial fibrillation, 13-14; changing of physician behavior, 413; correction of biases, 205; decision analysis and evidence-based, 389-91; explicit guideline development, 8; future of health care system, 16 half-cycle correction, and Markov

processes, 49
Harkness, A. R., 185–6
Hawkins, K. W., 275
Health Belief Model, 352
health care system: decision theory, 7–9;
future of, 14–18; importance of patient
involvement in, 334–6; local medical
knowledge, 366–8; trends in health
information for patients, 355. See also
managed care

health information: consumer access to, 351–5; evaluation of systems for, 349–51; formats of presentation, 339–46; management tools for, 394–6; physicians and access to decision-relevant, 393–4; principles of presentation and interactivity for, 346–9; topics of for

patients, 336-9; trends in, 355-7. See also education health insurance, perspective of and cost-effectiveness analysis, 10-11. See also third-party payers health maintenance organizations (HMOs): guidelines for patient care, 390; patient education, 355; symptom-based triage, 338. See also managed care Health on the Net Foundation (HON), 366 health plan, choice of, 339 Healthpoint, and computer kiosks, 342 health policy. See public policy Health Reference Center (Information Access Company, Foster City, CA), 343 health states: computers and utility elicitation, 324-6; descriptions of, 320, 324-6; macro-level analyses, 292-3; quality of life, 303-5; rating scales, 321; time trade-off (TTO) method, 83, 321; utility assessment, 67, 301, 307, 322-3. See also outcomes; preferences Health Utilities Index, 293, 304 Heckerling, P., 191 HELP system, 372 hemodynamic status, and accuracy analysis, 239 herniated intervertebral disc, 68 heterogeneity: Markov processes, 55-6; meta-analyses of randomized trials, 126-9, 133-4 hidden profile, and group decision making, 271-2 hindsight bias, 185-6, 187, 205 hip replacement surgery, 172, 193 HIV screening: decision trees, 23, 27-33, 39-41; influence diagrams, 34, 36; Markov processes, 49-54; sensitivity analyses, 37-9 HL-7 message protocol, 375 Hoffman, L. R., 273 Hoffrage, U., 394 Hogarth, R. M., 240 holistic outcomes, and utility assessment, 68, 87, 94, 98

Holtzman, S., 315, 316

343

home medical records, 338

home references, and patient information,



430 Index

homogeneity: Markov processes, 55–6; team decision making, 275 hormone replacement therapy, 197 hypertension, and propranolol, 159 hypothesis, diagnostic reasoning and testing of, 187

ibuprofen, and hip replacement, 193 ideographic approach, to lens model analyses, 236 implicit decisions, 25, 26f incorporation bias, 234 incremental utility, and Markov processes, 48, 49 indexing, of bibliographic databases, 121, 375 individual simulations, and Markov

processes, 57–8 influence diagrams, and decision models, 33–6, 60–1

information. See health information information content, and accuracy analysis, 214

information sampling model, and group decision making, 271

informed consent: bioethics, 258–64; patient education, 338; patient literacy, 354

Informed Patient Decisions Group, 342 Integrated Advanced Information Management Systems (IAIMS), 375 intellective tasks, 268

intensive care units (ICUs): life support systems, 263; mortality from pneumonia and accuracy analysis, 228, 234–5, 237, 238, 239

intention-to-treat analysis, 114 interactive video, and health information, 340–1

interface design, and health information, 346–8

interim analyses, and randomized trials, 117

internal validity, and evidence-based medicine, 113–14

Internet, and health information for patients, 341–2, 345–6, 351–2, 356. *See also* World Wide Web

INTERNIST-1 system, 373 interval scale, and utility assessment, 76 Ioannidis, John P. A., 168 Jadad, A. R., 122 Johannesson, M., 73–4 Johnson, E. J., 191 journals, medical, 120 judgments. *See* accuracy analysis justice, and bioethics, 254

Kahneman, D., 89, 105, 189, 198, 199–200, 203, 204 Kane, R. L., 77, 302 Kaplan, R. M., 303 Kaplan-Meier analyses, 111

Kassirer, J. P., 396, 397 Keeler, E. G., 175, 202 Keeney, R. L., 315

Kemka, A., 188 Kern, L., 187–8 kidney stones, 278 Kind, P., 302

Klayman, J., 188, 394 Klein, R. W., 60 knee injuries, 388–9

knowledge representation, models of, 375

Koehler, D. J., 184 Krahn, M. D., 21

lack of memory, and Markov processes, 44 Laird, N., 124, 135 Lamb, G. S., 274–5 language, and patient–physician

communication, 353 Larson, J. R., Jr., 279 late treatment, of HIV disease, 28

Lau, Joseph, 168 Laughlin, P. R., 268 Lawrence, W. F., Jr., 169–70

leaders, and team decision making, 274, 278–9

least-squares linear regression analyses, and subgroup analyses, 115 legal issues, and computer-based clinical

decision support, 376-9 Lenert, L. A., 325

lens model analyses, and accuracy analysis, 211–14, 235–7

Liberman, V., 184

life expectancy: decision tree for HIV screening, 29–30, 33; Markov processes for HIV screening, 51; prophylactic surgery for breast cancer, 318; sensitivity analysis for HIV screening, 37



More information

Index 431

life support systems, and bioethics, 262-3 life years, and cost-effectiveness analysis, 159, 160, 161f, 162 "limits to growth" model, of public policy, linear QALY model, 70-2, 73-4, 81-2, 87, 94–5, 98–9, 102, 104–5 listservers, and health information, 346 literacy, and access to health information, 353-4 lithotripsy, 203 liver transplantation, and discrete event simulation, 59 Llewelynn-Thomas, R. N. J., 67 Loewenstein, G., 258 logistic regression, and subgroup analyses, 115 lotteries: cumulative prospect theory, 106; decision weights, 200; expected utility theory, 75; preference reversals, 191; rank-dependent utility theory, 66, 88-9, 93 lovastatin, and hypertension, 159, 162 lung cancer, 189-90, 298 lupus, 276-7 Mackesy-Amiti, M. E., 191 macro-level decision makers, 147, 148, 291, 292-3

Mackesy-Amiti, M. E., 191
macro-level decision makers, 147, 148, 291, 292–3
MACTAR, 303
magazines, and health information, 340
Magnitude Estimation, and health state valuation, 294–5
Maier, N. R. F., 273, 279
mailing lists, and health information, 346
malpractice litigation, 378, 379
mammography. See breast cancer
managed care, and health policy, 145–6, 155. See also health maintenance organizations
Managing Anticoagulation Service Trial (MAST), 151–2
Mantel-Haenszel procedure, 115, 124
marginal nodes, and influence diagrams,

market prices, and opportunity costs, 173 Markov chain, 43, 46–7, 61

Markov cycle trees, 45 Markov models: advantages and

disadvantages of, 61-2; alternatives to, 54-9; complexity in, 51-4; definitions of terms, 42-5; description of, 41-2; evaluation of, 46-51; influence diagrams, 36; representation of, 45-6; risk attitude, 298; transition probabilities, 111 Markov node, 45 mastectomy, and breast cancer, 318 matrix algebra, 46-7 Mayo Clinic Family Healthbook (IVI Publishing, Eden Prairie, MN), 343 Mayo Clinic Family Pharmacist (IVI Publishing, Eden Prairie, MN), 343-4 McCarthy, B. D., 23 McClish, D. K., 241 McDonald, C. J., 364 McNeil, B. J., 189-90, 240, 267-8 MD Consult (WWW site), 365 mean probability scores, and accuracy analysis, 211-14, 215-16, 218, 219-26, 234, 242

media, and health information, 340 medical history, and physician–patient communication, 338. *See also* patient history

Medical Information Line (Strategic Systems, Inc., Waltham, MA), 340 medical records. See computer-based patient records: home medical records Medical Subject Headings (MeSH), 375 Medicare: cost data for gross costing, 172–3; home health care, 355 medicine, and study of decision making, 8–9 MEDLARS bibliographic search engine,

MEDLINE database, 120, 121, 365, 375 Medvec, V. H., 198 Meisel, A., 376 Mellers, B. A., 190

meso-level decision makers, 147, 291 meta-analyses using individual patient data (MIPD), 132

meta-analysis, of randomized trials: data extraction, 121–2; developing protocol for, 120; diagnostic tests, 129–31; formulas for pooled estimates, 134–5; general perspective on, 118–20; heterogeneity and, 126–9, 133–4; individual patient data, 132;



432 Index

meta-analysis, of randomized (cont.) Nease, R. F., 34 observational studies, 131; policy and, negligence theory, and malpractice 133; presentation of results of, 125; litigation, 378-9 qualitative analysis, 122-5; quantitative Nemeth, C. J., 274 synthesis of evidence, 123-5; sources of neural networks, and clinical decision data for, 120-1; statistically support, 372 nonsignificant results, 132-3. See also newsgroups, medical and health-related, randomized, controlled trials meta-level decision making, 291 newspapers, and health information, meta-regression analysis, 126-8 340 metascripts, and end-of-life care, 410 nodes: of decision trees, 24-5, 27; of metoprolol therapy, 113 influence diagrams, 34, 36 micro-costing, and cost-effectiveness no-memory property, of Markov models, analysis, 171-2, 173 54-6 micro-level decision makers, 147, 148, 291 nomothetic approach, to lens model Miller, A. C., 33 analyses, 236 Miller, D. T., 198 noncompliance, and patient education, Miller, Perry, 374 Miller, R. A., 376, 377 nonlinear probability weighting, MINDscape (WWW site), 366 hypothesis of, 90, 104, 105 minimum forecast variance, 218 nonmaleficence, and bioethics, 254 miscarriage, and testing for Down normal form, and decision tree, 26 syndrome, 259-60, 317 normalized discrimination index (NDI), Miyamoto, J. M., 74, 81, 86-7, 99-100, 103, normative model, of medical decision modifying variables, and subgroup making, 3-5 analyses in randomized trials, 115 nurses: accuracy analysis, 238; physicians' Moher, D., 122 scripts, 411; team decision making, 275 Monte Carlo simulation, 58, 60, 62 O'Brien, B., 294 Morgenstern, O., 86 Morrow, D., 354 observational data, and double-masked, Morss, S. E., 325 randomized trials, 111, 112 Mulrow, C. D., 130-1 observational studies, and meta-analysis, multimedia software, and utility elicitation, 324-5 occurrence groups, and accuracy analysis, multiple cue probability learning (MCPL), O'Connor, A. M., 190, 191 multiple endpoints, in randomized trials, odds ratio, and treatment effect in randomized trials, 123 Murphy's decomposition, 216, 217-18, Office of Management and Research 219-26 (OMAR), 150 MYCIN system, 372 omission bias, 195-7, 198, 258 myocardial infarction, and one-way sensitivity analysis, 37-9 cost-effectiveness analysis, 160 on-treatment analysis, and randomized Napodano, R., 275 oophorectomy, and ovarian cancer, 318 National Academy of Science, 364 opportunity costs, and cost-effectiveness National Cancer Institute (NCI), 346 analysis, 159, 162, 173, 177 National Institutes of Health (NIH), 366 oral contraceptives, 350

National Library of Medicine, 366 National Resource Planning Board, 153 organ transplantation programs, and

bioethics, 254, 261



Index 433

Osheroff, J. A., 369
Oskamp, S., 188
Ottawa Knee Rule, 388–9
outcome bias, 186–7
outcome index variance, and accuracy analysis, 218, 219, 226
outcomes: cost-effectiveness analysis, 39, 166–70; decision trees, 30; state descriptions, 320. See also health states ovarian cancer, 318
Owens, D. K., 34

pamphlets, and health information, 339 PANDA project (Stanford Medical Informatics), 317 Panel on Cost-Effectiveness in Health and Medicine, 10, 17, 159, 162, 163, 166, 168, 169, 173, 174, 176 Papanicolaou smears, 160, 162, 165 Parkinson's disease, 277 Parks, C. D., 280 path-independence, and Markov processes, 44 pathophysiology, of HIV infection, 52-4 patient chart, and case information, 270 patient-focused decision making, 18 patient handouts, 344 patient history, and accuracy analysis, 237. See also medical history Patient Outcome Research Team (PORT), 54, 150, 151 patient rights movement, 5-6 patients: computer-assisted clinical decision support, 369-75; as decision maker, 18, 314; handouts for, 344; importance of involvement in health care, 334-6; meta-analysis of individual data for, 132; tailoring health information for individual, 348-9; topics of health information for, 336-9; variability in self-reports, 270. See also autonomy; education; informed consent; physician-patient relationship Patient Self-Determination Act (1991),

Pauker, S. G., 189-90, 267-8, 396, 397

Person Trade-Off (PTO) method, and

health state valuation, 294, 295

perspectives: cost-effectiveness analysis, 9-11, 163-4, 166, 170-4, 177; decision models, 21-2 pesticides, 199 Peters, H., 74 Peto method, 124 photosensitivity, and lupus, 276 physical examination, and accuracy analysis, 237 physical relationships, and discrete event modeling, 59-60 Physician Data Query (PDQ), and National Cancer Institute, 346 physician-patient relationship: health education, 335; shared decision making and models of, 314 physicians: access to decision-relevant information, 393-4; accuracy analysis and studies of, 228-31; preferences for end-of-life treatment, 323; scripts and decision theory, 405-13; shared decision making, 314; as source of medical information, 344; supporting or altering of decision making by, 6; training of in decision theoretical reasoning, 391-1. See also clinical practice; physician-patient relationship pi function, 200. See also decision weights Pinto, J. L., 93 piroxicam, and hip replacement, 193 Plan-Do-Study-Act cycles, 412 Planning-Programming-Budgeting System, 153 Pliskin, J. S., 73 pneumococcal bacteremia, 164-5, 166-7, Pneumocystis carinii pneumonia, 125f pneumonia: accuracy analysis, 228, 231-5, 237, 239; meta-analysis of clinical trials, policy modeling, and health care decisions, 148-56. See also public policy pooled treatment effect (TE), 134-5 Poses, R. M., 238, 241, 396, 398 Powell, S., 241 power QALY model, 72-3, 80, 82, 84-5, 87-8, 95, 99, 100-1, 102 predictive models: policy modeling, 153-4; of stroke risk, 13 preference models, 65

Pennie, R. A., 191

pentamidine, 125f

perfect health, 169-70, 192



434 Index

preference reversals, and framing effects, 191, 192-4, 202 preferences: assessments of health states, 320; biases and values, 188-200; determinants of, 302-5; expected utility theory, 75; group-level decision analysis, 6; health information systems, 349; levels of decision making in health care, 291-3; models of, 65; nonutility-based methods for assessment of, 305-6; research on, 18; reversals of, 191, 192-4, 202; scaling problems, 300-1; utilities and normative theory of, 65; utility assessment, 66-7, 289-91, 293-300, 307 prenatal testing, for Down syndrome, 259-60, 316-17 prescriptive models: for health policy, 149; of medical decision making, 5-6 presentation bias, 121 present value, and cost-effectiveness analysis, 175 preventive health behaviors: future versus present outcomes, 201; patient involvement in health care, 337, 344 Prisoner's Dilemma, 257 probabilistic forecasts, and accuracy of judgment, 240-1 probability: computer-assisted clinical decision support, 371-2; decision tree for HIV screening, 30-1, 32f; equivalents and utility assessment, 78; hypothesis of nonlinear weighting of, 90; influence diagrams, 34; judgments of physicians, 397-8; multiple cue probability learning and feedback, 393 probability equivalent, and utility assessment, 78 probability trade-off methods, and patients' preferences, 305-6, 308 procedural invariance, 191, 192 productivity, and time costs, 174 propensity score, and accuracy analysis, 227, 244-5 prophylactic surgery, and breast cancer, proportional time trade-off (PTTO), 83, 85 propranolol, and hypertension, 159 prospective meta-analyses, 118–19 Prospect Theory, 190, 205 prostate cancer, 6, 196, 298, 318-19 proxies, and estimates of quality of life, 10 proximal events, and decision tree, 25 pseudo-certainty effect, 200 pseudodiagnosticity, 187-8 PSYCHLIT database, 121 psychology: behavior of physicians, 408-9; decision processes and future of health care system, 17-18; group decision making, 268, 270-1; preferences and theory of utility assessment, 66-7; subjective perception of risk, 258 psychophysical errors, and decision bias, 205 publication bias, 127 publication lag, and meta-regression analyses, 127 public policy: anticoagulant therapy for stroke prevention in patients with atrial fibrillation, 151-6; cost-effectiveness analysis, 17, 257; identity of makers of, 147; managed case, 145-6, 155; meta-analyses of randomized trials, 133; models of, 148-56; objectives of, 147-8; working definition of, 146-7 randomized trials, 122-5 cost-effectiveness analysis, 4, 168-70;

QMR system, 373-4 qualitative analysis, and meta-analysis of quality-adjusted life years (QALYs): group-level analyses, 291-2; HIV screening, 29-30; rank-dependent utility theory, 99-104; utility assessment, 70-3, 289-90. See also linear QALY model; power QALY model quality of life: perspective and assessment of, 9-10; utilities and, 290; valuation of health states, 303-5 quality scores, and meta-analysis of randomized trials, 122-3 quality weights, for health states, 169 Quality of Well-being Scale, 293, 304, 322 Quick Medical Reference (QMR), 277

Radiation therapy, 319
Raiffa, H., 175–6
random-effects model, and treatment
effects in randomized trials, 124, 134–5
randomized, controlled trials:
adjustments and stratification in,
116–17; advantages of, 111–13;
approaches to analysis, 114;



Index 435

computerized information services, 395; experiential evidence, 110; external validity, 114-15; internal validity, 113-14; multiple and secondary endpoints of, 117; safety issues, 118; subgroup analyses, 115-16. See also clinical trials; meta-analysis

rank-dependent utility (RDU) theory: empirical example of, 99-104; expected utility theory, 88-92; lotteries and, 66, 106; utility assessment, 92-9, 105

rating scales, for health states, 321 rational probability use, and accuracy analysis, 245

reading skills, and access to health information, 353

realistic probability use, and accuracy analysis, 245-6

real-time reminders, and computer-assisted clinical decision support, 369

receiver operating characteristics (ROC) curves: accuracy analysis, 211-14, 215, 219-26, 242, 246; meta-analysis of diagnostic tests, 129-30

recognition primed decision making, 406 recurrent state, and Markov processes, 43,

Redelmeier, D. A., 93-4, 184, 185, 193, 199, 203, 204, 216

reference case, and cost-effectiveness analysis, 11, 164

Regenstrief Medical Record System, 372 regret theory, 197-8

representation, and Markov processes, 45 - 6

residual category, and probabilities of outcomes, 185

Resource-Based Relative Value Scale,

resource allocation: bioethics and, 254, 260-4; cost-effectiveness analysis,

retrieval bias, 132

Revicki, D. A., 303

risk: appraisals of and patient involvement in health care, 337, 344; sensitivity analyses based on clinical trials and meta-analyses, 134; subjective perception of, 258; time horizon of diseases and interventions, 22-3; utility

assessment, 297-9. See also risk attitude: risk aversion; risk neutrality; risk seeking

risk-adjusted proportional time trade-off (PTTO), 85-6

risk attitude, 69, 298

risk aversion: expected utility theory, 102; framing effects, 190; time trade-off scores, 296; utility assessment, 69, 91-2 risk difference, and randomized trials. 123, 134

risk groups, and accuracy analysis, 246 risk neutrality: expected utility theory, 102; utility assessment, 69

risk posture: hypothesis of nonlinear probability weighting, 90, 103, 104, 105; time-trade off (TTO), 103, 104; utility assessment, 69-70, 74. See also risk attitude; risk aversion; risk neutrality; risk seeking

risk ratio, and treatment effect in randomized trials, 123, 134

risk seeking: expected utility theory, 102, 103, 104; framing effects, 190; utility assessment, 69, 91, 92

Ritov, I., 196, 197-8

RNA level, and HIV progression, 52 Roberts, Mark S., 168

Rogelberg, S. G., 275

Rosser and Kind Index, 293, 304 rule-based reasoning, 406

Rumery, S. M., 275

Sackett, D. I., 83

safety, and clinical drug trials, 118 safety monitoring boards, and interim analyses in randomized trials, 117 sample size, and meta-regression analyses, 127

Sanders, G. D., 325

Sattah, S., 192

Saville, P. D., 185-6

scaling problems, and preferences, 300-1

Schaffner, K. F., 376 Schittekatte, M., 280

Schrag, D., 318

Schreibner, C. A., 204

Schwartz, A., 190, 194

scoring formula, for health states, 292-3 scripts, and decision theory and

physicians', 405-13



436 Index

secondary endpoints, in randomized on use of, 377; patient education, 342-5, trials, 117 346-8; utility elicitation, 323-4. See also Secondary and Tertiary Prevention of computers Stroke (Stroke PORT), 150, 151 Sonnenberg, Frank A., 49, 168 Seiver, A., 316 Sox, H. C., 68, 77, 189-90, 267-8 selection bias, 227 specialization, of physician and decisions self-administered questionnaires, 304, to withdraw life support, 262-3 spectrum, and accuracy analysis, 233, self-care, and patient involvement in 246 - 7decision making, 337-8, 344 Speroff, T., 188, 212, 237 self-efficacy, and patient involvement in Stalmeier, P. F. M., 67, 192 standard gamble (SG) method: health medical care, 335 self-reports, variability in patient's, states, 321; rank-dependent utility 270 assumptions, 93, 94, 98, 99; utility assessment, 78, 80-1, 82-3, 86, 96, 293, Selker, H. P., 370 semantic compatibility, 192 295, 296-300, 303, 307; Wakker-Stiggelbout analysis of, 66 semi-Markov processes, 56-7 sensitivity analyses: decision models, 8, Stasser, G., 271 36-9; discount rates, 176; measurement states, and Markov processes, 43 of health outcomes, 168; meta-analyses state transition models: diagram of, 46f; of randomized trials and heterogeneity, event pathways, 168 133-4; time costs, 174 status, and group decision making, 272-4 sequences, evaluation of and role of time Stelfox, H. T., 122 Stevens, S. M., 241 in decision making, 202-4 sequential screening strategy, 40f Stewart, T. R., 225 set theory, and utility assessment, 76 Stigglebout, A. M., 66, 91, 93-4, 297, 298 SF36 (quality of life instrument), 304 stochastic trees, 62 Shafir, E., 193 strategy-based errors, 205 shared decision making: model of and stratification, and randomized trials, 116 - 17roles of patient and physician, 314; patient education, 338. See also team Strecher, V. J., 344, 348 decision making streptococcal pharyngitis, 228, 239, Shaw, P., 188 396-401, 406 Shepard, D. S., 73 stroke, and anticoagulant therapy in atrial Shortliffe, E. H., 369 fibrillation, 13-14, 151-6 side effects, of medications and clinical Stroke Policy Prevention Model (SPPM), 5, trials, 118 Sleath, B., 350 subgroup analyses, and randomized trials, 115-16 Slovic, P., 192 sufamethoxazole, 125f small-scale testing approach, to training of sunk cost bias, 194-5 physicians, 413 support groups, and patient education, smoking cessation interventions, 174, social health policy, 146-7 SUPPORT study (Study to Understand social support, and health information for Prognoses and Preferences for Outcomes and Risks of Treatment), 228, patients, 338-9 231, 234-5, 238-9, 240, 241, 401-5, 407 societal perspective, and cost-effectiveness analysis, 11, 163, 164, 166, 170, 173, 177 support theory, 184-5 sociodemographics, and patient surrogate decision makers, and end-of-life care, 402 preferences, 302 software programs: oversight committees Sutherland, H. J., 67, 298



More information

Tape, T. G., 237

Index 437

teaching hospitals, and group decision making, 273-4 team decision making: characteristics of group members, 272-6; distribution of information, 269-72; literature on, 267-9; research program on, 276-80 technological teams, and group decision making, 280 telecommunication, telephone, and television, as sources of health information, 340, 341-2 terminal nodes: of decision tree, 24f, 25, 27, 46; Markov processes, 51 test characteristics, and accuracy analysis, 214 test review bias, 234 tetanus, and vaccination, 162, 165 Thibodeau, L. A., 239 third-party payers: cost-effectiveness analysis, 164, 170-1; involvement of in medical decision making, 367. See also health insurance Thomas, W. H., 83 threshold, and sensitivity analysis, 38-9 threshold strategy, 396-7, 405, 406-7 Till, J. E., 67 time, and biases in decision making, 200 - 4time costs, and cost-effectiveness analysis, time horizon, of decision model, 22-3 time period, of cost-effectiveness analysis, 167 time preference, and preferences, 297 time trade-off (TTO): as measure of health status, 83, 321; risk posture, 103; utility assessment, 293, 294, 295-300, 303, 307 Torrance, G. W., 83, 86, 296, 297 tort liability, 378-9

randomized trials, 123-5, 134-5 Tversky, A., 89, 105, 184, 189-90, 192, 199-200, 268 Ubel, Peter A., 177, 258 uncertainty. See accuracy analysis Unic, I. J., 67 U.S. Public Health Service, 159 unpacking principle, 184-5 upstream events, and decision tree, 25 USENET newsgroups, 346 utilitarianism, and bioethics, 254, 256 utility assessment: basic notation, 74-5; computers and, 323-6; expected utility theory, 66, 75-88, 104-5; future research on, 105-6; health status, 322-3; preferences and, 66-7, 289-91, 293-300, 306-8; rank-dependent utility assumptions, 92-104; types of problems, 68-75 utility-based decisions, definition of, 18 utility elicitation: computers and, 323-4; rating or valuing of health states, 321 utility theory: advantages of, 65; decision-analytic principles, 256 U-Titer (software program), 323-4 vaccination: cost-effectiveness analysis,

simulations, 58; Markov processes, 43,

treatment effects, and meta-analysis of

Treadwell, Jon R., 103, 105, 203

value node, and influence diagram, 34-5 values: biases and preferences, 188-200; bioethics and, 261; cost-effectiveness analysis, 177; utility assessment, 306; value-focused approaches to decision making, 315, 326 Van Hiel, A., 280 Var(d), and accuracy analysis, 216–17, 219 variable discount rates, 201-2 variance: meta-regression analyses, 127; randomized trials and within-study, 124 Verhoef, L. C. G., 298 verification bias, 233 videotapes: descriptions of health states, 320; health information, 340-1 violent behavior, and judgments of psychiatrists, 240

164-5, 166-7, 169; omission bias, 196

Tower of Babel bias, 120

weights, 199

toxicity: adverse reactions in clinical drug

trials, 118; pesticides and decision

training: group decision making, 272; of

reasoning, 391-3; physicians' scripts,

transient state, and Markov processes, 43,

physicians in decision theoretical

412-13. See also education

transition probabilities: individual



438 Index

viral loads, and HIV infection, 53 Viramontes, J. L., 294 Visual Analog Scale (VAS), and utility assessment, 293, 294, 295, 296–7, 299–300, 307 Von Neumann, J., 86 Von Neumann-Morgenstern utility theory, 295, 321

Wachtler, J., 274
wages, and opportunity costs, 173
Waitzkin, H., 352
Wakker, P., 66, 73–4, 91, 93–4, 97–8, 298
Wakker-Stiggelbout analysis, of standard gamble method, 66
warfarin, 151
Weber, E. U., 190
WebTV, 341–2
Weinstein, M. C., 30, 73, 148, 149
Weiss, C. H., 155
Wigton, R. S., 393, 396
Wilcoxon nonparametric statistic, 129–30

Willingness-to-Pay (WTP) method, and health state valuation, 294, 295, 323 within-study variance, and randomized trials, 124 Wolf, F. M., 188 Working-Hotelling-type confidence bands, 130 work-up bias, 233 World Wide Web (WWW): computer-assisted clinical decision support, 365-6; computer literacy, 354; health information for patients, 341-2, 343, 344, 345-6, 356; support for patient decision making, 325-6. See also computers Wortmann, R. L., 185-6 Wu, G., 93

zero condition, and utility assessment, 74 zidovudine, 113

Yaniv, I., 225

Yates, J. F., 225